Semaglutide
Premium API
Semaglutide API
Semaglutide is the typical GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity. It can regulate blood sugar levels, reduce appetite, and support weight management. Morebio provides high-quality Semaglutide that meets global pharmaceutical standards to ensure the safety, efficacy, and consistency of the Semaglutide API.
Premium API
Semaglutide
Premium API
Semaglutide Description
Our generic APIs are specialized in GLP-1 RAs and related intermediates. These generic APIs are utilized for the treatment of diabetes and obesity. Obesity and Type 2 Diabetes are widespread diseases with considerable levels of morbidity and mortality globally, primarily in the form of cardiovascular disease(CVD). Therefore, GLP-1 RAs are becoming the preferred treatment for obesity and T2DM. Moreover, clinical evidence demonstrates that these agents also have the potential benefit for cardiovascular and kidney diseases.
Semaglutide API Application
Key Features&Benefits
US -FDA
DMF Certificate
Morebio achieves the FDA-DMF certificate for Semaglutide API (039115), Semaglutide Main Chain (039480).
Semaglutide API
DMF 039115
Semaglutide Main Chain
DMF 039480
Premium API
Genetic Synthesis of Semaglutide
Morebio applies new genetic technology for the synthesis of semaglutide API, our advanced technology generate semaglutide in fermentation of Escherichia coli(E. coli). Morebio has cutting-edge manufacturing facilities in industrial scales, this increase our production capability significantly. Our maximum batch size of semaglutide API can reach to 2.1 kg, and 200 kg in total per year. Even in pilot scale, we also have production capability of 30g.
The purity of semaglutide API in Morebio can reach more than 98%, our advanced manufacturing technology controls the impurities less than 2%. Comparing to Novo Nordisk, our simaglutide API has lower impurity.
In addition, in reason of our unique synthesis technology, Morebio semaglutide has more stability than the original semaglutide from Novo Nordisk.
our Quality
Quality Insurance
Mechanism
Semaglutide Reference
Indication
Semaglutide is a peptide-base therapeutic, it belongs to the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class. Semaglutide can mimic the effect of GLP-1, its modification has longer duration of action in the body with less administered frequency than the natural GLP-1 hormone. This makes it suitable for once-weekly dosing, and improves the patient adherence to treatment.
GLP-1
Glucagon-like peptide-1 (GLP-1) is a hormone in regulation of sugar blood levels, it is produced in the intestines. GLP-1 can stimulate insulin secretion from the pancreas, reduce glucagon production, slow down the stomach emptying, promote fullness feeling. All these effects improve glycemic control collectively, and cab be particularly beneficial for type 2 diabetes.
Semaglutide Reference
Action Mode
Semaglutide affects the glucose control in several different mechanisms, including: increasing insulin secretion, slowing down gastric emptying, reducing postprandial glucagon and food intake. GLP-1 has the major impact in glucose management, and semaglutide has an analog structure and simulates all the activities of GLP-1.
The innovative section of semaglutide is the structural modifications of amino acid substitution, which can generate stability against dipeptidyl peptidase-4, which is an enzyme that degrades incretins like GLP-1.
Semaglutide Reference
Structure
Semaglutide has 94% sequence homology with human GLP-1, it is the most critical receptor agonist of GLP-1. On the basis of liraglutide, semaglutide replace Lys with Arg at 34 position, replace Ala with 2-aminoisobutyric acid (AIB) at 8 position, and conjugate Lys with 18 carbon fatty acid chain at 18 position. Its affinity for albumin is six times of liraglutide, the half-life in human body is 165 hours.
The structure of semaglutide has (lysine acylation) with a spacer and C-18 fatty di-acid at position 26, and permits the specific binding to plasma albumin. These characteristics extend the half-life of semaglutide, increase patient compliance.